Press releases

On 18 June 2024, the exercise period for warrants of series TO3, which were issued in connection with Curasight A/S (“Curasight” or the “Company”) rights issue and directed issue of units earlier in 2024 (“TO3”) ended. In total 3,501 warrants of series TO3 were exercised, corresponding to a subscription rate of approximately 0.19 percent. Curasight is thus provided approximately DKK 54,440.6 before deduction of transaction related costs.

· Clinical Trial Application (CTA) submission marks progress in development of uTREAT[®] in aggressive brain cancer (Glioblastoma)
· Glioblastoma is the leading cause of brain cancer deaths in adults
· First patient to be dosed in H2 2025
· uTREAT represents a potential new treatment option in an area of high unmet medical need

Copenhagen, June 18, 2025 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) today announced submission of clinical trial application (CTA) to the European Medicines Agency (EMA) for the phase 1 trial of uTREAT® as a treatment for glioblastoma.

Copenhagen, Denmark, 3 June 2025 - Curasight A/S (“Curasight” or the “Company” - TICKER: CURAS) hereby announces that the exercise price for the warrants of series TO3 (”TO3”), which were issued in connection with the directed issue and rights issue of units the Company executed earlier during 2024, has been set. The exercise price for TO3 has been set to DKK 15.55 per share, which is the minimum price and the exercise period commences on 4 June 2025.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM DANISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE.

The Board of Directors of Curasight A/S (“Curasight” or the “Company” – TICKER: CURAS), has today, based on the authorization granted by the extraordinary general meeting on 23 April 2025, resolved on a directed issue of 977,768 shares to guarantors who have entered into guarantee commitments in the rights issue of shares announced on 4 April 2025 (the “Rights Issue”) and who have chosen to receive guarantee compensation in the form of newly issued shares (the “Directed Issue”). The subscription price in the Directed Issue amounts to DKK 1.98 per share, which corresponds to the subscription price in the Rights Issue. Payment is made by offsetting the guarantor's claim for guarantee compensation.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM DANISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE.

· The increase in share capital and number of shares arising from the rights issue of shares in May 2025 has now been registred with Danish Business Authority.

· It is expected that the first day of trading of the new shares from the rights issue will be 6 June 2025 and the estimated date for conversion to ordinary shares is 10 June 2025.

21 May 2025, Curasight A/S (“Curasight” or the “Company” - TICKER: CURAS) announced the outcome of the Company’s rights issue of shares, which had a subscription period running between 2 May and 16 May 2025 (the “Rights Issue”).

Copenhagen, Denmark, 28 May 2025 – today Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) held its Annual General Meeting at the office of DLA Piper Denmark, Oslo Plads 2, 2100 Copenhagen OE, Denmark

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM DANISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE.

The Board of Directors of Curasight A/S (“Curasight” or the “Company” – TICKER: CURAS), today announces the outcome of the rights issue of shares that the Board of Directors resolved to carry out on 24 April 2025 (the “Rights Issue”).

The outcome indicates that the Rights Issue has been subscribed to approximately 42.4 percent with and without exercise of subscription rights, of which approximately 41.5 percent were subscribed for by exercise of subscription rights and approximately 0.9 percent were subscribed for without exercise of subscription rights. The outcome thus indicates that approximately an additional 4.6 percent will be subscribed for by guarantors. Based on the outcome, Curasight will receive approximately DKK 47 million from the Rights Issue before issue costs and repayment of bridge loan to Fenja Capital II A/S.

Copenhagen, Denmark, 15 May 2025 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces in accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, the disclosure of participation by members of Curasight’s Board of Directors, Executive Management and team members in the Right Issue 2025 by exercise Curasight TO subscription rights to purchase new shares in the period May 12 - May 14, 2025.

The Board of Directors is pleased to invite shareholders to the Annual General Meeting of Curasight A/S (“Curasight” or the “Company” – TICKER: CURAS) on

Wednesday 28 May 2025 at 10.00 AM (CET) at the office of DLA Piper Denmark, Oslo Plads 2, 2100 Copenhagen OE, Denmark.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM DANISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE.

Friday, May 16, 2025, is the last day to subscribe to Curasight A/S (“Curasight” or the “Company” – TICKER: CURAS) ongoing rights issue of shares with preferential rights for existing shareholders (the “Rights Issue”). On 4 April 2025, the Board of Directors resolved on its intention to carry out the Rights Issue. The Extraordinary General Meeting held on 23 April 2025 authorized the Board to carry out the Rights Issue, and the Board subsequently resolved to carry out the Rights Issue on 24 April 2025. Please note that certain banks and custodians may have an earlier deadline for subscription in the Rights Issue than May 16, 2025. Shareholders are therefore advised to check with their bank or custodian to confirm whether an earlier deadline applies.

Summary of the Rights Issue

· Each holder of existing shares registered with Euronext Securities as of the record date, 1 May 2025, have been allocated forty-three (43) subscription rights for each existing share held. Eighteen (18) subscription rights entitle the holder to subscribe for one (1) new share.
· The subscription price is DKK 1.98 per share, and upon full subscription, Curasight will receive approximately DKK 100 million in gross proceeds through the Rights Issue before deduction of transaction costs
· The rights issue is covered by subscription undertakings of approximately DKK 27.7 million by Curium, Pentwater, members of the Board of Directors & management and existing shareholders. In addition, the Rights issue is covered by guarantee commitments from a number of external investors, corresponding to a total of approximately DKK 19.3 million. In total, the Rights Issue is thus covered by subscription and guarantee commitments totaling approximately DKK 47 million, which corresponds to approximately 47% of the Rights Issue.